OncoTargets and Therapy
ISSN 1178-6930 · Dove Medical Press · New Zealand · active 2008–2026
Metrics
- Scimago quartile (2025)
- Q2
- Cites per paper (2y)
- 2.2
- SJR
- 0.8
- h-index
- 111
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric (how the two differ). Citation rates differ enormously between fields, so compare within a discipline. What the other figures mean: journal quartile, SJR, h-index and article processing charge.
Data as of 8 November 2026 (venue index build).
Scimago Journal Rank 2025
In the Scimago Journal Rank 2025 edition, OncoTargets and Therapy is Q2 in all 2 of its subject categories.
| Subject category | Quartile | Rank in category |
|---|---|---|
| Pharmacology (medical) | Q2 | #106 of 286 |
| Oncology | Q2 | #195 of 426 |
- Cites per document (2 years, Scopus)
- 2.34
- Documents indexed in 2025 (Scopus)
- 97
The quartile is the one Scimago prints for each category. Rank is the journal's position by SJR among the journals Scimago lists in that category (#1 is the highest); “—” means we hold no rank consistent with that quartile. The document count is what Scopus indexed that year, which can be lower than a journal's full output. Source: SCImago Journal Rank 2025 edition, from Scopus data (scimagojr.com, CC BY-NC).
OncoTargets and Therapy is Q2 in all 2 of its Scimago subject categories (2025 edition; best category Pharmacology (medical): Q2, #106 of 286), with SJR 0.8 (Scimago) and an h-index of 111 (OpenAlex). Listed in Scopus, Web of Science, PubMed.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Indexing & access
- Indexed in
- ScopusWeb of SciencePubMed
- Access status:
- gold. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is OncoTargets and Therapy a predatory journal?
Our screening does not flag OncoTargets and Therapy. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is OncoTargets and Therapy indexed in Scopus or Web of Science?
Per our venue index, OncoTargets and Therapy appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of OncoTargets and Therapy?
Papers in OncoTargets and Therapy are cited about 2.2 times each within two years of publication, and Scimago places it in Q2, with an h-index of 111. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is OncoTargets and Therapy (Q1, Q2, Q3, or Q4)?
In the Scimago Journal Rank 2025 edition, OncoTargets and Therapy is Q2 in all 2 of its subject categories. By category: Pharmacology (medical): Q2, #106 of 286; Oncology: Q2, #195 of 426. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; OncoTargets and Therapy is cited about 2.2 times per paper over two years, with an h-index of 111.
What is the Web of Science (JCR) quartile of OncoTargets and Therapy?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for OncoTargets and Therapy. The open equivalent is its Scimago quartile, Q2, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is OncoTargets and Therapy open access?
Our index records its access status as "gold". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
Ready to submit? Tools for your next paper
Similar venues
Compare it with its peers: Ranked Oncology journals — ranked by Scimago quartile and cites per paper, predatory venues excluded.